Antibody-Drug Conjugates in Brain Metastases from Solid Tumors: Current Status,Therapeutic Potential,and Future Perspectives

doi:10.3870/j.issn.1672-0741.26.05.023

Abstract

Abstract: Brain metastases are a common and clinically challenging manifestation of solid tumors and are generally associated with poor prognosis and limited systemic treatment options.Effective intracranial drug delivery remains difficult because of the blood-brain barrier,the blood-tumor barrier,and the distinct immune microenvironment of brain metastases.Antibody-drug conjugates(ADCs),consisting of a monoclonal antibody,a chemical linker,and a cytotoxic payload,have shown substantial clinical value in multiple solid tumors.Accumulating evidence of intracranial activity in patients with brain metastases from breast cancer,lung cancer,and other solid tumors suggests that ADCs may provide new opportunities for systemic treatment in this setting.This review summarizes the potential mechanisms of action,clinical evidence,safety considerations,and future research directions of ADCs for brain metastases from solid tumors,aiming to inform optimization of therapeutic strategies for this patient population.

Key words: antibody-drug conjugates, brain metastases, blood-brain barrier, blood-tumor barrier, radiation necrosis, bystander effect, leptomeningeal disease

CLC Number:

R730.2

Dai Yunfei, Fei Jing. Antibody-Drug Conjugates in Brain Metastases from Solid Tumors: Current Status,Therapeutic Potential,and Future Perspectives[J]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong, 2026, 55(4): 597-605.

References

[1] Achrol A S,Rennert R C,Anders C,et al.Brain metastases[J].Nat Rev Dis Primers,2019,5:5.
[2] 中国医师协会肿瘤医师分会,中国医疗保健国际交流促进会肿瘤内科分会.肺癌脑转移中国治疗指南(2021年版)[J].中华肿瘤杂志,2021,43(3):269-281.
Clinical practice guideline for brain metastases of lung cancer in China(2021 version)[J].Chinese Journal of Oncology,2021,43(3):269-281.
[3] Myall N J,Yu H,Soltys S G,et al.Management of brain metastases in lung cancer:Evolving roles for radiation and systemic treatment in the era of targeted and immune therapies[J].Neurooncol Adv,2021,3(Suppl.5):v52-v62.
[4] Tan X L,Le A,Lam F C,et al.Current treatment approaches and global consensus guidelines for brain metastases in melanoma[J].Front Oncol,2022,12:885472.
[5] Kawauchi D,Narita Y.The curse of blood-brain barrier and blood-tumor barrier in malignant brain tumor treatment[J].Int J Clin Oncol,2025,30(7):1276-1286.
[6] Barrios J,Porter E,Capaldi D P I,et al.Multi-institutional atlas of brain metastases informs spatial modeling for precision imaging and personalized therapy[J].Nat Commun,2025,16(1):4536.
[7] Mansouri A,Ozair A,Bhanja D,et al.Stereotactic radiosurgery for patients with brain metastases:Current principles,expanding indications and opportunities for multidisciplinary care[J].Nat Rev Clin Oncol,2025,22(5):327-347.
[8] Paisana E,Cascão R,Alvoeiro M,et al.Immunotherapy in lung cancer brain metastases[J].NPJ Precis Oncol,2025,9:130.
[9] Bruzzone F,Barigazzi C,di Muzio A,et al.Exploring the role of ADCs in brain metastases and primary brain tumors:Insight and future directions[J].Cancers,2025,17(9):1591.
[10] Dumontet C,Reichert J M,Senter P D,et al.Antibody-drug conjugates come of age in oncology[J].Nat Rev Drug Discov,2023,22(8):641-661.
[11] Staudacher A H,Brown M P.Antibody drug conjugates and bystander killing:Is antigen-dependent internalisation required？[J].Br J Cancer,2017,117(12):1736-1742.
[12] Ocean A J,Starodub A N,Bardia A,et al.Sacituzumab govitecan(IMMU-132),an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers:Safety and pharmacokinetics[J].Cancer,2017,123(19):3843-3854.
[13] Cheng Y,Yuan X,Tian Q,et al.Preclinical profiles of SKB-264,a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor,demonstrated promising antitumor efficacy compared to IMMU-132[J].Front Oncol,2022,12:951589.
[14] Fu Z,Li S,Han S,et al.Antibody drug conjugate:The“biological missile”for targeted cancer therapy[J].Sig Transduct Target Ther,2022,7:93.
[15] Samantasinghar A,Sunildutt N P,Ahmed F,et al.A comprehensive review of key factors affecting the efficacy of antibody drug conjugate[J].Biomed Pharmacother,2023,161:114408.
[16] Mair M J,Bartsch R,Le Rhun E,et al.Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours[J].Nat Rev Clin Oncol,2023,20(6):372-389.
[17] Robert S M,Toth A,Lev S,et al.Antibody drug conjugates in metastatic brain tumors:Current landscape,therapeutic potential and challenges[J].J Neuro Oncol,2025,174(3):541-556.
[18] Kurihara H,Hamada A,Yoshida M,et al.(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients[J].EJNMMI Res,2015,5:8.
[19] Askoxylakis V,Ferraro G B,Kodack D P,et al.Preclinical efficacy of ado-trastuzumab emtansine in the brain microenvironment[J].J Natl Cancer Inst,2016,108(2):djv313.
[20] Kabraji S,Ni J,Sammons S,et al.Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases[J].Clin Cancer Res,2023,29(1):174-182.
[21] Zhou H,Zeng Y,Hida T,et al.The current landscape and pr-ospects of antibody-drug conjugates for lung cancer brain metastases:A narrative review[J].Transl Lung Cancer Res,2024,13(12):3778-3794.
[22] Montemurro F,Delaloge S,Barrios C H,et al.Trastuzumab emtansine(T-DM1)in patients with HER2-positive metastatic breast cancer and brain metastases:Exploratory final analysis of cohort 1 from KAMILLA,a single-arm phase Ⅲb clinical trial[J].Ann Oncol,2020,31(10):1350-1358.
[23] Ogitani Y,Aida T,Hagihara K,et al.DS-8201 a,a novel HER2-targeting ADC with a novel DNA topoisomerase Ⅰ inhibitor,demonstrates a promising antitumor efficacy with differentiation from T-DM1[J].Clin Cancer Res,2016,22(20):5097-5108.
[24] Modi S,Saura C,Yamashita T,et al.Trastuzumab deruxtecan in previously treated HER2-positive breast cancer[J].N Engl J Med,2020,382(7):610-621.
[25] Modi S,Jacot W,Yamashita T,et al.Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J].N Engl J Med,2022,387(1):9-20.
[26] Hurvitz S A,Kim S B,Chung W P,et al.Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial[J].ESMO Open,2024,9(5):102924.
[27] André F,Cortés J,Curigliano G,et al.A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2(HER2)-positive metastatic breast cancer with brain metastases[J].Ann Oncol,2024,35(12):1169-1180.
[28] Harbeck N,Ciruelos E,Jerusalem G,et al.Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases:A phase 3b/4 trial[J].Nat Med,2024,30(12):3717-3727.
[29] Bartsch R,Berghoff A S,Furtner J,et al.Final outcome analysis from the phase Ⅱ TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases[J].Neuro Oncol,2024,26(12):2305-2315.
[30] Bartsch R,Berghoff A S,Furtner J,et al.Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases:A single-arm,phase 2 trial[J].Nat Med,2022,28(9):1840-1847.
[31] Li B T,Planchard D,Goto K,et al.1321 MO Trastuzumab deruxtecan(T-DXd)in patients(pts)with HER2(ERBB2)-mutant(HER2 m)metastatic non-small cell lung cancer(NSCLC)with and without brain metastases(BMs):Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02[J].Ann Oncol,2023,34:S762-S763.
[32] Li Z,Wang Y,Sun Y,et al.Trastuzumab rezetecan,a HER2-directed antibody-drug conjugate,in patients with advanced HER2-mutant non-small-cell lung cancer(HORIZON-Lung):Phase 2 results from a multicentre,single-arm study[J].Lancet Oncol,2025,26(4):437-446.
[33] Bardia A,Hurvitz S A,Tolaney S M,et al.Sacituzumab govitecan in metastatic triple-negative breast cancer[J].N Engl J Med,2021,384(16):1529-1541.
[34] de Moura A,Loirat D,Vaillant S,et al.Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals:Efficacy,safety,and impact of brain metastases[J].Breast Cancer,2024,31(4):572-580.
[35] Fang W,Li X,Wang Q,et al.Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer:Multicentre,open label,randomised controlled trial[J].BMJ,2025,389:e085680.
[36] Fang W,Wu L,Meng X,et al.Sacituzumab tirumotecan in EGFR-TKI-resistant,EGFR-mutated advanced NSCLC[J].N Engl J Med,2026,394(1):13-26.
[37] Okajima D,Yasuda S,Maejima T,et al.Datopotamab deruxtecan,a novel TROP2-directed antibody-drug conjugate,demonstrates potent antitumor activity by efficient drug delivery to tumor cells[J].Mol Cancer Ther,2021,20(12):2329-2340.
[38] Pons-Tostivint E,Okamoto I,Ahn M J,et al.OA10.01 intracranial efficacy of datopotamab deruxtecan(dato-DXd)in patients with advanced/metastatic NSCLC in TROPION-Lung01[J].J Thorac Oncol,2025,20(10):S30-S31.
[39] Lisberg A,Ahn M J,Kitazono S,et al.Intracranial efficacy of datopotamab deruxtecan(Dato-DXd)in patients(pts)with previously treated advanced/metastatic non-small cell lung cancer(a/m NSCLC)with actionable genomic alterations(AGA):Results from TROPION-Lung05[J].JCO,2024,42(16_Suppl):8593.
[40] Bardia A,Jhaveri K,Im S A,et al.Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer:Primary results from TROPION-Breast01[J].J Clin Oncol,2025,43(3):285-296.
[41] Camidge D R,Bar J,Horinouchi H,et al.Telisotuzumab vedotin monotherapy in patients with previously treated c-met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase Ⅱ LUMINOSITY trial[J].J Clin Oncol,2024,42(25):3000-3011.
[42] Horinouchi H,Cho B C,Camidge D R,et al.Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing,EGFR-mutated locally advanced/metastatic non-small-cell lung cancer(NSCLC)after progression on prior osimertinib[J].Ann Oncol,2025,36(5):583-591.
[43] Alder L,Trapani D,Bradbury C,et al.Durable responses in patients with HER2⁺ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan[J].NPJ Breast Cancer,2023,9(1):19.
[44] Preusser M,Garde-Noguera J,García-Mosquera J J,et al.Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors:The phase 2 TUXEDO-3 trial[J].Nat Med,2025,31(8):2797-2805.
[45] Cheo S W,Li M S C,Huang D D,et al.Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer:What have we accomplished so far？[J].Cancer Treat Rev,2026,143:103083.
[46] Lebow E S,Pike L R G,Seidman A D,et al.Symptomatic necrosis with antibody-drug conjugates and concurrent stereotactic radiotherapy for brain metastases[J].JAMA Oncol,2023,9(12):1729.
[47] Koide Y,Nagai N,Ito M,et al.Impact of concurrent antibody-drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases:A multicenter retrospective study[J].Int J Radiat Oncol,2024,120(2):e246.
[48] Debbi K,Benderra M A,Medioni J,et al.Safety and efficacy of combined trastuzumab-deruxtecan and concurrent radiation therapy in breast cancer.The TENDANCE multicentric French study[J].Breast,2025,80:104421.
[49] Yu H A,Goto Y,Hayashi H,et al.HERTHENA-Lung01,a phase Ⅱ trial of patritumab deruxtecan(HER3-DXd)in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy[J].J Clin Oncol,2023,41(35):5363-5375.
[50] Ho E C H,Qiu R,Miller E,et al.Antibody drug conjugates,targeting cancer-expressed EGFR,exhibit potent and specific antitumor activity[J].Biomed Pharmacother,2023,157:114047.
[51] Cavaco M,Frutos S,Oliete P,et al.Conjugation of a blood brain barrier peptide shuttle to an Fc domain for brain delivery of therapeutic biomolecules[J].ACS Med Chem Lett,2021,12(11):1663-1668.
[52] Szecskó A,Mészáros M,Simões B,et al.PepH3-modified na-nocarriers for delivery of therapeutics across the blood-brain barrier[J].Fluids Barriers CNS,2025,22(1):31.
[53] Chen Y,Liu C,Wen X,et al.Treatment of HER2-positive breast cancer with brain metastases using anlotinib and trastuzumab deruxtecan:A case report[J].Int J Women’s Heal,2024,16:1277-1283.